Your browser doesn't support javascript.
Therapeutic use of specific tumour necrosis factor inhibitors in inflammatory diseases including COVID-19.
Patel, Serena; Wadhwa, Meenu.
  • Patel S; Downing College, Regent Street, Cambridge CB2 1DQ, UK; Ipswich Hospital, Heath Road, Ipswich IP4 5PD, UK.
  • Wadhwa M; NIBSC, MHRA, Blanche Lane, South Mimms, Hertfordshire EN6 3QG, UK. Electronic address: Meenu.Wadhwa@nibsc.org.
Biomed Pharmacother ; 140: 111785, 2021 Aug.
Article in English | MEDLINE | ID: covidwho-1252500
ABSTRACT
Coronavirus disease 2019 (COVID-19) has caused significant devastation globally. Despite the development of several vaccines, with uncertainty around global uptake and vaccine efficacy, the need for effective therapeutic agents remains. Increased levels of cytokines including tumour necrosis factor are significant in the pathogenesis of COVID-19 and associated with poor outcomes including ventilator requirement and mortality. Repurposing tumour necrosis factor blocker therapy used in conditions such as rheumatoid arthritis and inflammatory bowel disease seems promising, with early feasibility data showing a reduction in circulation of pro-inflammatory cytokines and encouraging the evaluation of such interventions in preventing disease progression and clinical deterioration in patients with COVID-19. Here, we examine the biological activities of tumour necrosis factor inhibitors indicative of their potential in COVID-19 and briefly outline the randomised control trials assessing their benefit-risk profile in COVID-19 therapy.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Tumor Necrosis Factor Inhibitors / SARS-CoV-2 / COVID-19 Drug Treatment / Inflammation Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Animals / Humans Language: English Journal: Biomed Pharmacother Year: 2021 Document Type: Article Affiliation country: J.biopha.2021.111785

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Tumor Necrosis Factor Inhibitors / SARS-CoV-2 / COVID-19 Drug Treatment / Inflammation Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Animals / Humans Language: English Journal: Biomed Pharmacother Year: 2021 Document Type: Article Affiliation country: J.biopha.2021.111785